GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allarity Therapeutics Inc (NAS:ALLR) » Definitions » Cyclically Adjusted FCF per Share

Allarity Therapeutics (Allarity Therapeutics) Cyclically Adjusted FCF per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Allarity Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Allarity Therapeutics's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2023 was $-127.450. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-06-10), Allarity Therapeutics's current stock price is $ 0.501. Allarity Therapeutics's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2023 was $0.00. Allarity Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Allarity Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Allarity Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allarity Therapeutics Cyclically Adjusted FCF per Share Chart

Allarity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
- - - - -

Allarity Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Allarity Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Allarity Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allarity Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Allarity Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Allarity Therapeutics's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-127.45/129.4194*129.4194
=-127.450

Current CPI (Dec. 2023) = 129.4194.

Allarity Therapeutics does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate it.


Allarity Therapeutics  (NAS:ALLR) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Allarity Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Allarity Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Allarity Therapeutics (Allarity Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
24 School Street, 2nd Floor, Boston, MA, USA
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
Executives
Laura Benjamin director 168 GOODRICH ST., LUNENBURG MA 01462
Joseph Walter Vazzano director 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Gerald W. Mclaughlin director 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
David Roth director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joan Yvonne Brown officer: Chief Financial Officer C/O GOLDEN PHOENIX MINERALS, INC., 1675 EAST PRATER WAY, #102, SPARKS NV 89434
Steve Carchedi director, officer: Chief Executive Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Steen Knudsen officer: Chief Scientific Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Jens Erik Knudsen officer: Chief Financial Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Soren Gade Jensen director 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Duncan Moore director C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Thomas Jensen officer: SVP, Information Technology 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
James G. Cullem officer: SVP, Chief Business Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Marie Foegh officer: Chief Medical Officer 210 BROADWAY, STE 201, CAMBRIDGE MA 02139
Sass & Larsen Aps 10 percent owner VESTERGARDSVEJ 6, GREVE G7 DK-2670
Leon Sass 10 percent owner JERNBAEK ALLE 5, HELSINGE G7 DK-3200

Allarity Therapeutics (Allarity Therapeutics) Headlines